Intralesional cemiplimab for patients with early-stage cutaneous squamous cell carcinoma: Results from a dose-escalation study with expansion cohorts.
Low-dose intralesional cemiplimab showed antitumor activity against early-stage skin cancer with manageable side effects, though findings involve a small patient group.
This dose-escalation study with expansion cohorts examined efficacy and safety of low-dose intralesional cemiplimab. Intralesional cemiplimab showed antitumor activity with an acceptable safety profile, but the small cohort limits generalizability.
What the study was
- Study design
- Dose-escalation study with expansion cohorts
- Population
- patients with early-stage cutaneous squamous cell carcinoma
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of the American Academy of Dermatology
Why it surfaced
Retained as a standard-priority dose-escalation study with expansion cohorts after PubMed abstract review; the score reflects clinical relevance, design strength, novelty, and population need under the v1.3 conservative rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.